Introduction
Individuals with coronary artery disease (CAD) have a lower life expectancy than non-CAD patients. 1, 2 Although mortality rates in patients with CAD have decreased, potentially by the advancement of medical therapies, new surgical practices, and more aggressive treatment of risk factors, 1 investigation into additional ways to reduce morbidity and mortality are needed. Depression has become increasingly recognized as one such factor of interest. Recently, the American Heart Association recommended that depression following an acute coronary syndrome should be considered a risk factor for poor prognosis since evidence supports its association to allcause and cardiac mortality, as well for non-fatal cardiac events. 3 Depression is a common, debilitating illness and is considered as one of the most burdensome diseases in the world. 4 Major depression has been shown to be associated with greater medical symptom burden, disability, medical costs, poor adherence to medical regimens, overall diseases, and death. [4] [5] [6] [7] [8] [9] There is a bidirectional relationship between depression and CAD. 10 The adverse health risk behaviours and physiological changes associated with depression may increase the risk for poor outcomes. 10, 11 Likewise, the distress, symptom burden, and physiological impairments associated with CAD can result in a higher risk for depression. Nevertheless, the presence of depression is associated with an increased risk of morbidity and mortality. 4 The prevalence of major depression among CAD patients ranges from approximately 10% to 30%, with even more patients having some level of depressive symptoms. [12] [13] [14] [15] While studies consistently report the association of depression to mortality, these evaluations often utilize depression diagnoses occurring within 30 days of the CAD event, 16 thus determination of which disease occurred first are difficult. It is unknown whether depression is associated with the risk of mortality when the diagnosis of depression is made at a time substantially later than the CAD event. This study sought to determine the association of a depression diagnosis more clearly resulting after CAD diagnosis with all-cause mortality.
Methods

Study objectives
The primary objective of this study was to determine if the risk of allcause mortality associated with depression among patients with CAD varies with the time between the diagnosis of CAD and the follow-up diagnosis of depression.
The secondary objectives of this study were to determine if the magnitude of risk changed for a follow-up depression diagnosis among subgroups of CAD patients. Subgroups to be evaluated included patients <65 vs. > _65 years of age, females vs. males, those with or without prior history of depression, patients' indication for angiography [stable angina, unstable angina, or myocardial infarction (MI)], and those with and without a prior MI.
Study patients
Intermountain Healthcare patients (N = 24 137) who were > _18 years of age underwent angiography at LDS Hospital or Intermountain Medical Center (Salt Lake City, UT, USA) and were determined to have significant CAD (stenosis > _70% in at least one major coronary artery) were studied (September 1993 to April 2016). Intermountain Healthcare is a large, electronically integrated healthcare organization that has 22 hospitals and over 185 clinics and provides the majority of healthcare for people in the state of Utah. This study was in compliance with the Declaration of Helsinki and was approved by the Intermountain Institutional Review Board.
Demographics, risk factors, and clinical assessments
Baseline was defined as the date of CAD diagnosis as determined by angiography. At the time of angiography, the attending cardiologist completed a standardized form that included information on previous or current disease states and angiographic clinical assessments and results. Cardiovascular (CV) risk factors collected included hypertension, hyperlipidaemia, diabetes, smoking history, renal failure, and family history of CAD (first-order relative had suffered CV death, MI, or coronary revascularization before age 65 years). Prior history of CAD diagnosis, MI, heart failure (HF), atrial fibrillation (AF), stroke, transient ischemic attack (TIA), and peripheral vascular disease (PVD) were also reported. Clinical presentation (reason for angiography) included stable angina (stable exertional symptoms only), unstable angina (progressive symptoms or symptoms at rest), or MI. Method of treatment (medication only, percutaneous coronary intervention, or coronary artery bypass surgery) and the location and percent stenosis of each diseased vessel were described.
Other metrics were abstracted from the electronic medical record and included age, sex, body mass index (BMI) and ejection fraction (EF), which was assessed by echocardiography or left ventriculography. A prior history of depression was determined by International Classification of Diseases (ICD) codes (ICD-9 codes: 296.2-296.36 and 311; ICD-10: F32.x or F33.x). Discharge medications were also recorded, including statins, beta-adrenergic receptor blockers (beta-blockers), angiotensin converting enzyme inhibitors, digoxin, angiotensin II receptor blockers, and diuretics.
Patient follow-up and event assessment
A follow-up depression diagnosis was determined by ICD codes (ICD-9 codes: 296.2-296.36 and 311; ICD-10: F32.x or F33.x) and occurred at or post-discharge of CAD hospitalization. A follow-up depression diagnosis could have occurred in an outpatient, inpatient, or emergency setting. Timing of a new diagnosis of depression was defined as the date that a depression ICD code was first reported. The outcome of this study was all-cause mortality. Deaths were determined from three different data sources, which include Intermountain Healthcare electronic records, State of Utah death certificates, and the Social Security Administration death master file. Patients not listed as deceased in any registry were considered to be alive. Patients were followed for 9.7 ± 6.1 (median: 8.9 ) years for the occurrence of death.
Statistical analysis
The v 2 test and Student's t test were used to examine univariable associations of a follow-up clinical diagnosis of depression to baseline and clinical characteristics. To confirm the associations determined by univariable analysis, multivariable Cox regression analysis (SPSS, version 22.0) was performed to determine hazard ratios (HRs) of a follow-up depression diagnosis and confounding factors to death. Depression was evaluated as a time-varying covariate in multivariable Cox hazard regression models to control for the differing lengths of time between CAD diagnosis and depression diagnosis among patients. The time varying covariate was created by multiplying the time to depression and a follow-up depression diagnosis. Covariables used in the modelling were identified a priori and listed in Table 1 . As intermediate endpoints, patients were evaluated for the occurrence of a follow-up MI (n = 5022), HF hospitalization (n = 2094), and stroke (n = 1262) since they are risk factors for death. These intermediate endpoints were used as covariables in the primary outcome model. A landmark analysis was performed to confirm that a depression diagnosis occurring at differing lengths of time after CAD diagnosis continued to be associated with death. The time points used in the landmark analysis for when a depression diagnosis occurred were <1 year, 1-3 years, 3-5 years, and >5 years. Only patients alive and who did not have depression diagnosis prior to the time point being evaluated were included in the analysis. Kaplan-Meier survival curves and log rank test were performed at landmark time points. Final models entered significant (P < 0.05) and confounding (>10% change in beta-coefficient) covariables.
Results
A total of 24 137 patients met criteria and were studied. Among these patients, 3646 (15%) were diagnosed with depression following CAD diagnosis. Mean days from CAD diagnosis to depression was 4.6 ± 4.5 (median: 3.2) years. A total of 27.1% of patients had their Patient characteristics, risk factors, and clinical assessments stratified by patients who had no follow-up depression diagnosis and those who had a follow-up depression diagnosis are shown in Table 1 .
Patients with a follow-up depression diagnosis were younger, had a greater proportion of females, more risk factors, and comorbidities. These patients less often presented with an MI.
A total of 1819 (49.9%) and 7820 (38.2%) patients with and without a depression diagnosis died during follow-up (P < 0.0001), respectively. Since depression was identified at varying time points throughout follow-up, it was evaluated as a time-varying covariate. This was done to control for the differing lengths of time between CAD diagnosis and depression diagnosis among patients. A follow-up depression diagnosis was significantly associated with all-cause mortality [univariable HR = 2.18 (2.07, 2.29), P < 0.0001]. This strong Figure 1 shows the variables that were significantly associated with death and included in the final model. A follow-up depression diagnosis was found to be the strongest predictor of death. A landmark analysis confirmed the risk associated with a depression diagnosis with death after differing lengths of time follow-up ( Table 2 and Figure 2) . Figure 3 shows the association of a follow-up depression diagnosis to death among a variety of subgroups. The subgroups evaluated include those <65 vs. > _65 years of age, male vs. female, no prior depression diagnosis, presentation (stable angina vs. unstable angina vs. MI), and no prior MI vs. prior MI. Among each subgroup, a follow-up depression diagnosis was strongly associated with death, with HRs ranging from 1.84 (stable angina) to 2.25 (unstable angina).
Discussion
A follow-up depression diagnosis at any time following CAD diagnosis was found to be highly associated with death. It more strongly predicted death than any other baseline characteristic, risk factor, comorbidity, severity of CAD, and follow-up events. These results emphasize the growing recognition that depression is a risk factor for poor outcomes. Further, it shows that continual screening of depression is needed among all patients with CAD regardless of age, sex, prior history of a depression diagnosis, reason for angiography, and prior MI.
Depression is a common and significant health care problem and our study showed that it can occur at any time point following a CAD diagnosis. Its identification is significant since it is the leading cause of disability among adults in high-income counties. 17 Depression affects the quality of life for both patient and caregivers. The economic health burden, both directly and indirectly, is significant. 18 Both biological and behavioural mechanisms have been suggested to explain the association between depression and CV disease. Patients with depression have been reported to have reduced heart rate variability, enhanced platelet activation, impaired vascular function, and increased inflammatory markers. [19] [20] [21] [22] [23] [24] Further, they tend to have poorer diets, reduced exercise regimens, reduced medication adherence, and more stress. [25] [26] [27] [28] Overall, depression decreases the opportunity of successful modifications of cardiac risk factors resulting in higher healthcare costs and poorer outcomes. 18, 29, 30 Assessment for depression is not routinely performed despite the numerous studies reporting associations between depression and poor outcomes among patients with CV disease. 31 Reasons for this may include focus on the treatment of symptoms and risk factors that are more measurable, the availability of depression screening tools, infrastructure that allows for the treatment of depression, and the perception of ability to treat depression. Further, social stigma that has traditionally occurred with mental illness may make both clinician and patient reluctant to initiate such a discussion. The American Heart Association, endorsed by the American Psychiatric Association, has stated that cardiologists should include depression in their assessment of the patient and has provided guidelines on screening and treatment strategies. 32 Two recent studies of post-MI patients have reported improvement in symptoms and outcomes in treated depressed patients compared with non-treated depressed patients. 33, 34 In particular, the 1-year mortality risk was similar for treated depressed patients and non-depressed patients, but nontreated depressed patients had a significantly increased risk of death when compared with non-depressed patients. 33 These studies along with the results of this study reinforce the need for depression to be part of the patient treatment strategy. Studies evaluating the association of depression and poor CV outcomes usually evaluate depressive symptoms within a relatively short time-frame from the cardiac event. A meta-analysis of 22 different studies evaluating post-MI patients evaluated the association of a depression diagnosis that occurred within 30 days of MI to all-cause mortality and found that a depression diagnosis was associated with an odds ratio of 2.38 for all-cause mortality. 16 Another meta-analysis found that a depression diagnosis within 1-2 years after the MI was associated with a doubling of risk for death. 35 Recently, a study was performed among patients with stable obstructive CAD as determined by coronary angiogram without a history of depression for the association of a depression diagnosis throughout a patient's followup for death. 36 Patients were followed for a mean of 3 years, with depression being diagnosed among 18 .8% of people. Over half of the The total number of patients at risk, the number of depression diagnoses within that time interval, the total number of deaths after that time point, and adjusted HR with 95% CI, and P-values are shown. HR, hazard ratio; CI, confidence interval. Like our study, this study supports the need for continual depression screening. Our study goes further in having followed patients for a mean of 10 years and evaluating all patients diagnosed with CAD, regardless of age, sex, presentation, history of a depression diagnosis, and prior MI. A limitation of this study includes that depression was defined by ICD codes. Therefore, the severity of depressive symptoms is unknown, coding errors may have occurred, and determination of depression may not be consistent among providers resulting in an over-or underestimation of the prevalence of depression. However, the prevalence of depression for this study is within the range reported by other studies evaluating CAD patients, albeit on the lower end of the range. Additionally, ICD codes do not allow for the determination of the severity of depression symptoms, but rather whether there was a depression diagnosis or not. Verification of the accuracy of the ICD codes could not be made given the large number of patients within the study. However, in a previous study assessing depression, a random chart review was performed and found that approximately 90% of the patients that were identified by depression ICD codes had depression discussed within their medical notes. It is also possible that a depression diagnosis could have occurred outside of the health system. Another limitation of this study is the possibility of residual confounding. Though a strength of this study is the many baseline and follow-up risk factors that were available for adjustment, unmeasured confounding may still be present. For example, we did not have information on the severity of depressive symptoms, change of depressive symptoms, treatment of depression, socio-economic status, behavioural changes, and functional impairment. A selection bias may have occurred among patients typically recognized to be more likely to be depressed (i.e. females and patients with more comorbidities) to receive a depression diagnosis. However, a followup depression diagnosis was consistently the strongest predictor of death among all subgroups. It is possible that other comorbidities had a time-varying association with death that was not controlled for. Like any other cohort study, this study is unable to determine causality and temporality.
Strengths of this study include its large sample size and long prospective follow-up. Data within this study were collected on standardized forms and by similar means. Not only did this study have a variety of baseline risk factors available for adjustment, it also had information on follow-up events. Heart failure is a strong risk factor for death and by being able to adjust by the occurrence of a follow-up HF hospitalization in the analysis allows for the reduction of residual confounding, which accords greater credence for the association between depression and death. Another strength of this study is its ability to identify a depression diagnosis during follow-up. In most studies, the identification of depression is made through survey or interview at a single point in time. These assessments do not take into account the manifestation or diagnosis of depression after hospitalization. This study is able to identify a clinical diagnosis of depression at multiple time points and assess its impact on death by modelling depression as a timevarying covariate and then confirming the association through a landmark analysis.
Conclusion
A depression diagnosis at any time following CAD diagnosis was found to be a strong predictor of death among patients initially undergoing coronary angiography. Incident depression more strongly predicted death than any other baseline characteristic, risk factor, comorbidity, severity of CAD, and follow-up events. The association of depression with mortality was also found to exist and be consistent in each of a variety of patient subgroups. These results emphasize the need for continued depression screening among all patients with CAD during clinical follow-up care.
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